Physician profile
Leila Lildar
NPI 1821627662
$1,511.78
in general payments reported to CMS, 2019-2025
8 companies · $1,374 in 2025
The $1,374 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $138 · 2025: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $440.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $440.00 | 2025 | Korlym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $372.39 | 2025 | |
| Amgen INC. | $149.99 | 2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $140.00 | 2025 | |
| Lilly USA, LLC | $138.13 | 2024 | Mounjaro |
| Verona Pharma, INC. | $122.60 | 2025 | Ohtuvayre |
| Kowa Pharmaceuticals America, INC. | $121.84 | 2025 | Zoryve |
| Tactile Systems Technology INC | $26.83 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leila Lildar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.